07:00 , Apr 21, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Imaging

Approach Summary Licensing status Publication and contact information Imaging Stabilized, cholecystokinin B receptor (CCKBR; CCK2R)-targeting radiopeptide for tumor imaging A CCK2R-targeting radiopeptide could be useful for imaging tumors. Earlier CCK2R-targeting agents were potentially toxic, showing...
07:00 , Sep 20, 2010 |  BC Week In Review  |  Clinical News

TT-223: Development discontinued

Transition and partner Eli Lilly discontinued development of TT-223 after a double-blind, placebo-controlled, U.S. Phase Ib trial in about 150 patients showed that the compound in combination with LY2428757 , a Phase II pegylated glucagon-like...
07:00 , Aug 12, 2010 |  BC Innovations  |  Targets & Mechanisms

The GPCR-cancer connection

Researchers from Roche 's Genentech Inc. unit have identified a host of somatic mutations and gene copy number alterations across human cancers that represent potential targets for the disease. 1 Nineteen of the 112 candidate...
08:00 , Feb 1, 2010 |  BC Week In Review  |  Clinical News

TT-223: Phase II data

Data from a double-blind, dose-ranging, U.S. Phase II trial in about 80 patients on background metformin or thiazolidinedione therapy showed that 3 mg once-daily subcutaneous TT-223 met the secondary endpoint of significantly reducing HbA1c from...
07:00 , Aug 20, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colon cancer Cholecystokinin B receptor (CCKBR; CCK2R) Studies in mice suggest that antagonizing CCK2R could help treat colorectal cancer. The CCK2R ligand progastrin can cause...
07:00 , Mar 30, 2009 |  BC Week In Review  |  Clinical News

TT-223: Phase Ib started

Eli Lilly began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate 2 or 3 mg subcutaneous TT-223 given once daily in combination with 14 mg of Eli Lilly's subcutaneous LY2428757 , a pegylated glucagon-like...
07:00 , Mar 26, 2009 |  BC Innovations  |  Distillery Techniques

Technology: Imaging

This week in techniques Approach Summary Licensing status Publication and contact information Imaging Cholecystokinin receptor-selective labeling for in vivo tumor targeting Radioiodine-labeled benzodiazepines could be useful for in vivo identification of tumors that bind drugs...
08:00 , Feb 9, 2009 |  BC Week In Review  |  Clinical News

TT-223: Completed Phase II enrollment

Transition completed enrollment of about 80 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating subcutaneous TT-223 given once daily. Eli Lilly licensed exclusive rights to develop and commercialize the product last year (see...
07:00 , Jul 2, 2007 |  BC Week In Review  |  Clinical News

E1-I: Final Phase IIa data

In a double-blind, placebo-controlled, U.S. Phase IIa trial in 30 Type II diabetics with baseline HbA1c levels of >=7%, mean HbA1c levels were reduced by 0.94-1.21% from baseline at 2-6 months post-treatment. Specifically, HbA1c levels...
07:00 , Mar 26, 2007 |  BioCentury  |  Product Development

Reaching proof of concept

Reaching proof of concept Obesity Company Product Description Target/ Mechanism Milestones Alizyme Cetilistat (ATL-962) Lipase inhibitor Lipase Start Ph III 1H07 (A) Amylin Pramlintide/leptin Synthetic amylin analog/recombinant leptin Amylin receptor/leptin receptor Ph II data 07...